Lymph node ratio as best prognostic factor in triple‐negative breast cancer patients with residual disease after neoadjuvant chemotherapy

Although lymph node status (ypN) is one of the most important prognostic factors of survival, the lymph node ratio (LNR) has emerged as an equitable factor. We aimed to compare the prognostic value of both ypN and LNR in patients with residual triple‐negative breast cancer (TNBC) after neo‐adjuvant chemotherapy (NAC). This was a retrospective cohort study of patients treated in a tertiary care center during the period 2000‐2014. We stratified the population based on LNR (≤0.20, 0.20‐0.65, and >0.65) and ypN (N1, N2, and N3) status. The overall survival (OS) and progression‐free survival (PFS) were estimated with Kaplan‐Meier curves and the log‐rank + test. We further compared patient mortality and disease recurrence using multivariate Cox regression analysis. We evaluated 169 patients with a median follow‐up of 87 months. At 2 years of follow‐up, patients with low‐risk LNR compared to those with moderate and high risk had a higher PFS (54% vs 31% vs 18%, respectively; P